Follow‐up
PD, thrombocytopenia, neutropenia
NEUTROPENIA, ADVERSE EVENTS, DISEASE, THROMBOCYTOPENIA, SECONDARY
Treatment was discontinued in the following cases: (1) Imaging showed progressive disease (PD) requiring alternative treatment. (2) Patients were eligible for transplantation and requested to discontinue treatment and then underwent transplantation. (3) Patients themselves requested to withdraw from the clinical trial or withdrawal was considered medically necessary by the investigators.Chemotherapy with cisplatin and cytarabine was reduced by 20% (rituximab, decitabine, and dexamethasone did not require reduction) if patients experienced grade 3–4 adverse events (AEs) that did not resolve within 2 weeks.Recombinant human granulocyte colony‐stimulating factor and recombinant human thrombopoietin were administered to patients who developed neutropenia and thrombocytopenia as supportive therapy or secondary prevention in the next cycle.